Nodal and metastatic prostate cancer at diagnosis increased after 2008, when the USPSTF recommended against PSA screening for men aged 75 or older, and again when it expanded the recommendation for all men.
In a head-to-head comparative study involving PCa patients with early biochemical recurrence following radical surgery, PSMA PET/CT had significantly higher cancer detection rates than fluciclovine PET/CT.
Updates include adjuvant radiotherapy for patients with adverse pathologic findings, hormonal therapies.
The proportion of men with metastatic prostate cancer who develop visceral metastases rose from 26% in 2009 to 40% in 2016, a study found.
Standardized incidence ratio highest for prostate cancer for men, nasopharynx cancer for women.